Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Netherlands-based company Pharming Group NV has formed a research collaboration with the UK's NovaThera to commercialize pioneering technologies combining biology, biomaterials and bio-photonics expertise.
Subscribe to our email newsletter
The technologies were developed at the Imperial College London, the base from which NovaThera was originally formed.
Pharming and NovaThera are to collaborate on combining NovaThera’s proprietary biomaterial products with Pharming’s recombinant proteins such as human collagen, fibrinogen, lactoferrin and C1 inhibitor. The collaboration takes advantage of the complementary capabilities of products from Pharming and NovaThera and could provide Pharming with several new products.
Pharming will retain commercial rights to the new products and ownership of the intellectual property developed in the collaboration. NovaThera will receive milestone payments and royalties linked to successful development of new products.
“NovaThera’s research capabilities in the fields of tissue engineering and regenerative medicine provide an exciting opportunity for Pharming,” said Dr Francis Pinto, CEO of Pharming. “Pharming will further strengthen its pipeline with new products and build on the value of its proprietary recombinant proteins.”
“The collaboration with Pharming allows NovaThera to bridge academia, science and industry to develop new innovative products for various applications,” said Gareth Roberts, CEO of NovaThera.